An Open Label, Multi-Center Study to Investigate the Safety of Cannabinoid (GWP42003-P) in Children With Medication Resistant Epilepsy
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 22 Aug 2016
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy
- Focus Expanded access; Therapeutic Use
- Acronyms CBD
- 04 May 2015 New source identified and integrated (ClinicalTrials.gov record : NCT02397863)
- 22 Apr 2015 Data from 137 patients in this expanded access program were presented a the American Academy of Neurology Annual Meeting 2015, according to a GW Pharmaceuticals media release.
- 22 Apr 2015 A GW Pharmaceuticals media release announced physician reports in 137 patients in this expanded access program.